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Abstract
Background: Tissue factor (TF) pathway inhibitor-1 (TFPI) is expressed in several malignant tissues- and cell lines
and we recently reported that it possesses anti-tumor effects in breast cancer cells, indicating a biological role of
TFPI in cancer. The two main splice variants of TFPI; TFPIα and TFPIβ, are both able to inhibit TF-factor VIIa (FVIIa)
activity in normal cells, but only TFPIα circulates in plasma. The functional importance of TFPIβ is therefore largely
unknown, especially in cancer cells. We aimed to characterize the expression and function of TFPIα, TFPIβ, and TF in
a panel of tumor derived breast cancer cell lines in comparison to normal endothelial cells.
Methods: TFPIα, TFPIβ, and TF mRNA and protein measurements were conducted using qRT-PCR and ELISA,
respectively. Cell-associated TFPI was detected after phosphatidylinositol-phospholipase C (PI-PLC) and heparin
treatment by flow cytometry, immunofluorescence, and Western blotting. The potential anticoagulant activity of
cell surface TFPI was determined in a factor Xa activity assay.
Results: The expression of both isoforms of TFPI varied considerably among the breast cancer cell lines tested,
from no expression in Sum149 cells to levels above or in the same range as normal endothelial cells in Sum102
and MDA-MB-231 cells. PI-PLC treatment released both TFPIα and TFPIβ from the breast cancer cell membrane and
increased TF activity on the cell surface, showing TF-FVIIa inhibitory activity of the glycosylphosphatidylinositol-
(GPI-) anchored TFPI. Heparin treatment released TFPIα without decreasing the cell surface levels, thus indicating
the presence of intracellular storage pools of TFPIα in the breast cancer cells.
Conclusion: GPI-attached TFPI located at the surface of breast cancer cells inhibited TF activity and could possibly
reduce TF signaling and breast cancer cell growth locally, indicating a therapeutic potential of the TFPIβ isoform.
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Introduction
Tissue factor (TF) pathway inhibitor-1 (TFPI) is a
plasma serine protease inhibitor, which is mainly known
for its role in the coagulation cascade, being responsible
for the modulation of TF induced blood coagulation.
The human TFPI gene is positioned on chromosome 2
and spans about 70kb [1,2]. Two main splice variants
are transcribed from TFPI; TFPIα and TFPIβ [1,3,4].
Both mRNAs encode a signal peptide that redirects the
translating ribosome to the ER, inserting the protein into
the ER lumen as it is translated. The proteins are post-
translationally modified in the ER and in Golgi, and are
then transported by vesicles to the exterior of the cell
[5]. The mature TFPIα protein comprises 276 amino
acids and contains an N-terminal end, three Kunitz-type
inhibitor domains, and a positively charged C-terminal
tail [1]. Intracellular TFPIα is thought to either remain
soluble or bind to an unknown co-factor containing a
glycosylphosphatidylinositol (GPI) anchor [5]. Depend-
ing on the nature of TFPIα inside the cell, the protein is
either secreted or indirectly attached to the outer cell
wall after transportation to the outer cell membrane
[5,6]. In comparison, the mature TFPIβ protein com-
prises 223 amino acids. It shares amino acids 1–181 with
TFPIα, and thus the N-terminal end and the first two
Kunitz-type domains, but has a different C-terminal end
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containing a GPI attachment signal that exclusively loca-
lizes it to the cell membrane [6].
In vivo, only TFPIα is detected in circulating blood
and this isoform is therefore considered to be important
in arresting the coagulation initiation. Heparin treatment
rapidly increase the release of TFPI from endothelial
cells both in vivo [7] and in vitro [8,9], which may be an
important anticoagulant effect of heparins [10,11]. Cell-
associated TFPIα and TFPIβ are both able to inhibit the
activity of the TF-factor VIIa (FVIIa) catalytic complex
in normal cells in vitro [12] although their contribution
to the anticoagulant effect is not completely understood.
In cancer, TF expression and function has been exten-
sively studied and the non-haemostatic effects of TF in
promoting cancer cell metastasis and angiogenesis are
well documented [13-19]. In contrast, TFPI has shown
anti-tumor effects. We recently investigated the bio-
logical relevance of TFPI in breast cancer cells through
overexpression and knockdown studies and found that
both isoforms exerted tumor suppressing properties,
such as increased apoptosis and reduced proliferation-
and migration/invasion in vitro [20-22]. Furthermore,
several cancer cell lines and tumors have been reported
to express TFPIα [23,24], and enhanced levels of both
TFPIα and TFPI-factor Xa (FXa) complexes have been
detected in plasma of patients with solid tumors [25,26],
supporting that TFPI may be involved in malignant dis-
ease mechanisms.
To further explain the role of TFPI in malignant dis-
ease, we have in the present study aimed to characterize
TFPI by investigating the expression and localization of
TFPIα and TFPIβ, and also the relation to TF expression
and activity, in a panel of breast cancer cell lines. Since
the endothelium is considered to be the predominant
site of TFPI synthesis, the TFPI characteristics of the
breast cancer cells were compared to normal endothelial
cells. The selected breast cancer cell lines have been
derived from different breast tumors, and are classified
as basal- or luminal-like, and primary or metastatic
according to the subtype and origin of the tumor, re-
spectively. We report here considerable variations in the
expression of both TFPI isoforms among the various
breast cancer cell lines tested. The expression ranged
from not detected to levels comparable to and even
higher than observed in normal, primary endothelial
cells. TFPIα was detected in the cell medium and on the
surface of breast cancer cells, attached through a GPI
anchor, while TFPIβ was exclusively located on the cell
surface. The GPI-attached, cell bound TFPI was found
to be functionally active, and to our knowledge, demon-
strating for the first time anticoagulant properties of
TFPI expressed on the surface of breast cancer cells.
Heparin treatment increased the TFPIα levels in the
supernatant without altering the cell surface levels,
indicating the presence of intracellular storage pools of
TFPIα in the breast cancer cells.
Results
TFPIα and TFPIβ mRNA and protein expression levels
Quantitative real-time PCR using reverse primers spe-
cific for TFPIα and TFPIβ was performed to determine
the relative mRNA expression of the two isoforms in the
various breast cancer cell lines. The results were normal-
ized against the TFPI expression level in the primary
human coronary artery endothelial cells (HCAECs)
(Table 1), while the TFPI negative non-human Chinese
hamster ovary (CHO) cell line was used as a negative
control in Figure 1A. The breast cancer cell lines
expressed TFPIα mRNA in the following high to low
order: Sum102 > MDA-MB-231 > MCF-7 > SK-BR-3 >
BT-474 > ZR-75-1 > Sum149. TFPIβ mRNA was
expressed in the same high to low order as TFPIα
(Table 1), and the expression of the two isoforms corre-
lated significantly (r = 0.94, p < .001). As illustrated in
Figure 1A, the Sum102 breast cancer cells expressed
twice as much TFPIα and β mRNA as the MDA-MB-
231 cells, and 17- and 4-fold more TFPIα and TFPIβ
mRNA, respectively, than the non-cancerous breast epi-
thelial cell line ME16C2. The Sum102 cell line expressed
twice as much TFPIα and similar levels of TFPIβ as the
HCAECs and the endothelial cell line EA.hy926, while
the MDA-MB-231 cells expressed similar levels of
TFPIα, but only half the amount of TFPIβ as the
HCAECs and EA.hy926 cells (Table 1 and Figure 1A).
Compared to the HCAECs, the relative TFPIα mRNA
expression was 10-fold lower in the non-cancerous
breast epithelial cells ME16C2 and 100 – 1000-fold
lower in the breast cancer cell lines SK-BR-3 and MCF-7
(Table 1). Virtually no TFPIα or TFPIβ mRNA was
expressed by the BT-474, ZR-75-1, and the Sum149 cell
lines (Figure 1A and Table 1).
TFPI antigen levels were measured using the free and
total TFPI enzyme-linked immunoabsorbent assay
(ELISA) kits. The free TFPI kit detects an epitope in the
third Kunitz domain of TFPI and thereby measure only
TFPIα. The total TFPI kit detects an epitope between
the first two Kunitz domains and it therefore able to
measure both TFPI isoforms. ELISA of recombinant
TFPI1-161, which lacks the third Kunitz domain, con-
firmed this, as only the total, but not the free kit
detected the truncated TFPI (data not shown). Secreted
TFPIα was measured in the cell medium, and TFPIα
mRNA and protein levels correlated significantly
(r = 0.94, p = .002). The breast cancer cell lines secreted
TFPIα in the following high to low order: Sum102 >
MDA-MB-231 > MCF-7 and SK-BR-3. No detectable
levels of TFPIα protein were secreted by the BT-474,
ZR-75-1, and Sum149 cells (Figure 1B and Table 1). The
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Table 1 Characterization of TFPI and TF in a selection of tumor derived breast cancer cell lines and normal cells
Cell types Description/Subtype Origin Invasiveness
(In vitro)*
TFPIα mRNA (RQ) TFPIβ mRNA (RQ) Relative Free TFPIα
(secreted)
TF mRNA (RQ) Relative fl† TF
(cell-associated)
SUM102 Breast epithelial, basal-like Tumor (primary) Invasive 1.85 1.02 1.41 129 105
MDA-MB-231 Breast epithelial, basal-like Tumor (metastatic) Invasive 0.87 0.46 0.31 894 705
MCF-7 Breast epithelial, luminal-like Tumor (metastatic) Non-invasive 0.01 0.02 0.04 0.45 0.96
SK-BR-3 Breast epithelial, luminal-like Tumor (metastatic) Non-invasive 3E-03 0.02 0.05 1.58 1.64
BT-474 Breast epithelial, luminal-like Tumor (primary) Non-invasive 8E-04 6E-03 n.d 2.63 1.32
ZR-75-1 Breast epithelial, luminal-like Tumor (metastatic) Non-invasive 7E-04 5E-03 n.d 3.55 2.33
SUM149 Breast epithelial, basal-like Tumor (primary) Invasive 2E-04 4E-03 n.d 4373 948
HCAEC Coronary artery endothelial Primary (normal) Non-invasive 1.00 1.00 1.00 1.00 1.00
EaHy926 Umbilical vein endothelial Transformed Non-invasive 1.11 0.83 0.38 0.62 0.61
ME16C2 Breast epithelial, basal-like Primary (immortalized) Invasive 0.11 0.25 0.28 336 170
* from references [38-42].
RQ - relative quantification calculated using 18sRNA as endogenous control. All values were calculated against HCAEC expression as a normal endothelial reference.
† full length.
n.d. - not detected, below lowest standard.
TFPI and TF mRNA and protein levels were measured using qRT-PCR and ELISA in the breast cancer cells and in the non-cancerous breast epithelial cells ME16C2 and umbilical vein endothelial cell line EaHy926. All
values were compared to the primary human coronary artery endothelial cells HCAEC and presented as relative values, mRNA results by the comparative Ct method and antigen levels by direct comparison.
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Sum102 cell line secreted 40% more TFPIα than the
HCAECs, while the MDA-MB-231 cells secreted TFPIα
levels within the range of the endothelial cell line EA.
hy926 and the non-cancerous breast epithelial cells
ME16C2 (Figure 1B and Table 1). The breast cancer cell
lines that expressed abundant TFPIα and TFPIβ origi-
nated from both primary and metastatic basal-like
tumors and have previously been shown to display inva-
sive characteristics in vitro (Table 1).
TF mRNA and antigen
TF protein levels were measured in the cell lysate and
correlated significantly with mRNA expression in all the
cell lines (r = 0.99, p < .001). Moreover, the expression
of TF associated with TFPI expression in all breast can-
cer cell lines tested except the Sum149 cells. Compared
to the endothelial cells HCAEC, high levels of TF
mRNA were detected in the basal-like, invasive breast
cancer cell lines Sum102, MDA-MB-231, and Sum149,
and also in the non-cancerous breast epithelial cells
ME16C2. In contrast, the luminal-like, non-invasive
breast cancer cell lines MCF-7, SK-BR-3, BT-474, and
ZR-75-1 expressed low levels of TF mRNA, in the same
range as the endothelial cells HCAEC and EA.hy926
(Table 1). The breast cancer cells Sum149 and MDA-
MB-231 expressed 13- and 3-fold more TF mRNA, re-
spectively, compared to the non-cancerous ME16C2
cells, while the Sum102 cell line expressed less TF
mRNA relative to ME16C2 cells, but 130-fold more than
the HCAECs (Table 1).
Cell-associated TFPI in breast cancer cells versus normal
endothelial cells
The breast cancer cell lines Sum102 and MDA-MB-231,
possessing high TFPI expression, were further analyzed
to determine the nature of any cell-associated TFPI.
Cleavage of the GPI anchors by phosphatidylinositol-
phospholipase C (PI-PLC) treatment resulted in a sig-
nificant 1.5- and 5.3-fold increase in free and total TFPI
antigen levels, respectively, in the Sum102 cell super-
natant (Figure 2A), and a corresponding 49% decrease in
total, but not free TFPI antigen levels, in the cell lysate
(Figure 2B). PI-PLC treatment reduced the amount of
TFPI positive Sum102 cells from 31.8 (± 3.9) to 3.9
(± 0.2) as measured by flow cytometry, corresponding to
an approximately 75% removal of the cell surface TFPI
(Figure 2C). Immunostaining demonstrated a clear, but
not a complete removal of cell surface TFPI after PI-
PLC treatment of the cells (Figure 2D). This effect was
also apparent when a TFPIα specific antibody was used
(data not shown). Western blot analysis of deglycosy-
lated PI-PLC supernatants showed that both isoforms of
TFPI were released after PI-PLC treatment of Sum102
cells (Figure 2E). Slightly heavier bands than previously
reported for TFPI was observed, which may be due to
cancer cell specific modifications. No significant increase
in free and a minor increase in total TFPI antigen was
detected in the MDA-MB-231 cell supernatants after PI-
PLC treatment (Figure 2F), and a slight reduction in cell
surface TFPI levels was seen by flow cytometry
(Figure 2G). No significant decrease in free or total TFPI
was detected in the cell lysate of these cells after PI-PLC
treatment (data not shown).
Heparin treatment of Sum102 cells increased the free
and total TFPI antigen levels 2.9- and 2.6-fold, respect-
ively, in the cell supernatant (Figure 3A). A correspond-
ing 48% and 32% decrease in free and total TFPI,
respectively, was seen in the cell lysate (Figure 3B). PI-
PLC pre-treatment prior to heparin treatment resulted
in an additional 60-70% increase in free and total TFPI
antigen levels in Sum102 supernatant compared to hep-
arin treatment alone (Figure 3A). A reduction in TFPI
Figure 1 TFPI expression in different breast cancer cell lines and normal cells. Cells were seeded in 6-wells trays to reach ~80% confluence
in three days before media were collected and cells lysed for RNA isolation. (A) Relative TFPIα and TFPIβ mRNA expression measured using qRT-
PCR. ΔΔCt values were calculated using 18s rRNA as an endogenous control and the TFPI negative, non-human CHO cells as a negative control.
(B) Secreted TFPIα protein measured in cell media and normalized to total protein amounts. Mean values + SD (n = 3) are presented.
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levels was also observed in cell lysates, especially appar-
ent in the total TFPI levels (Figure 3B). A 2.1- and 2.3-
fold increase in free and total TFPI antigen levels,
respectively, was observed in the supernatant of MDA-
MB-231 cells after heparin treatment, though no add-
itional increase was seen when the cells were pre-treated
with PI-PLC (Figure 3C). Heparin reduced free and total
TFPI levels in the cell lysate by 40% and 34%, respect-
ively, and pre-treatment with PI-PLC reduced the levels
even further (Figure 3D). Flow cytometry showed no re-
duction of cell surface TFPI levels after heparin treat-
ment in either cell line (Figure 3E), and no additional
reduction in cell surface TFPI was observed after heparin
treatment of PI-PLC pre-treated cells (data not shown).
The TFPI characteristics in the breast cancer cell lines
were very similar to those observed in the primary endo-
thelial cells HCAEC. In the supernatant, free and total
TFPI antigen levels were increased 1.3- and 2.4-fold, re-
spectively (Figure 4A) after PI-PLC treatment. Comple-
mentary, the free and total TFPI antigen levels in the
cell lysate were reduced by 27% and 40%, respectively
(Figure 4B). Measured by flow cytometry, TFPI positive
cells were reduced from 200.4 (±16.9) to 43.1 (±1.9) fol-
lowing PI-PLC treatment, corresponding to a 90% re-
moval of TFPI from the endothelial cell surface
(Figure 4E, left panel). As demonstrated for Sum102 and
MDA-MB-231 cells, no reduction in cell surface TFPI
was observed by flow cytometry after heparin treatment
of HCAECs (Figure 4E, right panel), though total TFPI
levels were increased 2-fold in the cell supernatant and
reduced by 38% in the cell lysate. Furthermore, free TFPI
was increased 2.9-fold in the supernatant and reduced
by 46% in the cell lysate (Figure 4C and D). Sequential
treatment with PI-PLC followed by heparin did not re-
duce TFPI cell surface levels any further than PI-PLC
alone (data not shown), which is equivalent to the obser-
vations in the breast cancer cell lines. Moreover, PI-PLC
pre-treatment of HCAEC cells followed by heparin
released 50% more free TFPI into the supernatant and
reduced cell lysate levels additionally compared to hep-
arin alone (Figure 4C and D) as seen in the Sum102
breast cancer cells.
TF-FVIIa activity and co-localization
To explore the potential anticoagulant activity of the
breast cancer and endothelial cell-associated TFPI, we
measured the TF activity on the Sum102, MDA-MB-231
and HCAEC cell surface indirectly by a chromogenic
FXa activity assay. The generation of FXa on the surface
of Sum102 and HCAEC cells increased significantly by
1.3- and 2-fold, respectively, following PI-PLC treatment
(Figure 5A and C). A small 10% increase in FXa levels
was observed on MDA-MB-231cells after PI-PLC treat-
ment, although not significant probably due to the abun-
dant TF levels in these cells (Figure 5B). Treating cells
with anti-TFPI blocking antibody resulted in higher FXa
activity than PI-PLC treatment in all cells tested
(Figure 5A-C), indicating that additional non-GPI bound
TFPI with anticoagulant activity is present on the cell
surface. ELISA results confirmed that PI-PLC treatment
did not alter the TF antigen levels in the cells compared
to untreated controls (data not shown). Control experi-
ments performed in the absence of FVIIa showed no
generation of FXa (data not shown), and the addition of
anti-TF blocking antibody prior to analysis suppressed
the FXa generation significantly, except in the HCAEC
cells (Figure 5A-C). Immunostaining with both anti-
TFPI and anti-TF antibodies simultaneously demon-
strated a co-localization of these proteins at the surface
of Sum102 cells (Figure 5D, upper panels), which was
diminished after PI-PLC treatment (Figure 5D, bottom
panels).
Discussion
In the present study, we have characterized the mRNA
and protein expression of two isoforms of TFPI (α and
β) and also TF, in a panel of breast cancer cell lines in
comparison to normal endothelial cells. We have pro-
vided novel evidence that non-cancerous and malignant
breast epithelial cells express TFPIβ protein. The breast
cancer cell lines are classified as either basal- or
luminal-like according to the subtype of the tumor they
were derived from. In general, basal-like breast cancer
cells tend to lack hormone receptors and are more inva-
sive than luminal-like cells [27,28]. The TFPI expression
(See figure on previous page.)
Figure 2 PI-PLC treatment of Sum102 and MDA-MB-231 cells. Serum-starved cells were treated with SFM (untreated) or PI-PLC (1 U/mL) for 2
hours before the supernatant was removed and cells lysed or collected for flow cytometry analysis. Total and free TFPI antigen measured in the
supernatant (A and F) and lysate (B) of untreated and PI-PLC treated Sum102 (A and B) and MDA-MB-231 (F) cells. Mean values + SD (n ≥ 8) of
three to six independent experiments are presented. All statistical comparisons were conducted between PI-PLC treated samples and untreated
controls. Flow cytometry analysis of untreated (black, solid) and PI-PLC treated (black, broken) Sum102 (C) and MDA-MB-231 (G) cells. One
representative experiment of three is shown. (D) Fluorescence images of SFM + glycerol (untreated, left panel) and PI-PLC (middle panel) treated
Sum102 cells stained with antibody against both isoforms of TFPI. The right panel shows a secondary antibody background control staining. One
representative experiment of three is shown. (E) Western blot of supernatants from SFM + glycerol (untreated) and PI-PLC treated Sum102 cells.
Samples were deglycosylated and incubated with a polyclonal anti-human TFPI antibody.
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seemed to correlate well with invasiveness and basal-like
origin of the cells, except for the TFPI negative Sum149
cell line. Among the cell lines tested, TFPI expression was
detected in the following high to low order; Sum102 >
MDA-MB-231 > MCF-7 > SK-BR-3 > BT-474 > ZR-75-1 >
Sum149, which is comparable to data from Kao and co-
workers [28] when we extracted the TFPI expression results
from their publicly available data file of gene expression
profiles of different breast cancer cell lines. The TFPI ex-
pression also seemed to correlate with the growth rate of
the cells as MDA-MB-231, MCF-7, BT-474, and ZR-75-1
have a doubling time of approximately 23, 29, 72, and 80
hours, respectively. Moreover, high expression of TF was
also observed in cells expressing TFPI which may contrib-
ute to the growth of the cells. Previously, the MDA-MB-
231 cells were also shown to express TFPI mRNA and
protein [23]. The relative mRNA ratios between the two
TFPI isoforms correlated well in all the breast cancer cell
lines in terms of TFPIα being the major isoform, which is
consistent with our findings and previous results in endo-
thelial cells [6]. A positive correlation between TFPIα
mRNA and secreted antigen levels was observed in the cell
lines. However, HCAEC cells secreted 3-fold more TFPIα
protein than MDA-MB-231 and EA.hy926 cells, although
TFPIαmRNA levels were similar. This could imply that less
TFPIα is cell-associated in these cells compared to the
MDA-MB-231 breast cancer and EA.hy926 endothelial
cells.
Recently, Girard and co-workers reported that TFPIβ
was the sole TFPI isoform associated with the SK-Hep-1
endothelial cell surface through a GPI anchor [29]. In
contrast to this, our findings indicated that both TFPIα
and TFPIβ were attached to the surface of the Sum102
breast cancer cells through GPI anchors as confirmed by
ELISA and Western blotting of deglycosylated PI-PLC
treated supernatants. Moreover, a significant increase in
both free and total TFPI was observed after PI-PLC
treatment of the normal endothelial cells HCAEC in this
study, although ELISA results indicated that TFPIβ was
the most abundant GPI-attached isoform in both cell
types. Endothelial cells have previously been shown to
express TFPIα on the cell surface [30], and in a study by
Piro and Broze the endothelial cells ECV304 (later iden-
tified as a bladder carcinoma cell line [31]) were shown
to express both TFPIα and TFPIβ on the surface [12].
These results, together with our findings, may indicate
cell type dependent differences in the expression of a
GPI-attached cofactor for TFPIα. Intriguingly, no reduc-
tion in free TFPI was observed in Sum102 cell lysates
after PI-PLC treatment as seen in the HCAEC cell
lysates. This may be due to higher background levels of
free TFPI in the Sum102 cell lysate than in the super-
natant. Thus it seems likely that the amount of GPI-
attached TFPIα was insignificant compared to the total
amount of cell-associated TFPIα in these cells. Low
levels of TFPI seemed to be released from the MDA-
MB-231 cells after PI-PLC treatment, which may be due
to the relative low TFPIβ expression in these cells com-
pared to the Sum102 and endothelial cells, or to other
structural differences on the surface of these cells that
made the GPI anchors inaccessible to PI-PLC.
Heparin treatment resulted in the release of TFPI from
the Sum102 and MDA-MB-231 breast cancer cells in a
similar manner to that observed in normal endothelial
cells in this and a previously study [32]. Moreover, our
findings support the growing evidence that the full
length TFPIα is the exclusive TFPI isoform released
upon heparin treatment as similar levels were detected
using either ELISA kit. Heparin treatment released TFPI
from breast cancer cells without reducing cell surface
levels, which is consistent with what was observed in
endothelial cells in this and other studies [6,8,9,30].
Thus, our findings indicate that the breast cancer cells
possessed intracellular storage pools of TFPIα in a simi-
lar manner to that suggested for normal endothelial
cells. The basic mechanism and exact cellular
localization of this heparin-releasable TFPI is, however,
currently unknown. In contrast to what was reported
previously for HUVECs [32], serum was not necessary
for the release of TFPIα by heparin in the breast cancer
cells or HCAECs, although serum did increase the
amount of TFPI released by heparin. Treatment with PI-
PLC uncovered a heparin-releasable TFPI pool that was
not accessible before treatment, since PI-PLC prior to
heparin treatment released additional TFPIα from the
Sum102 and HCAEC cells. Thus, some GPI-attached
cell surface protein(s) seemed to interfere with the abil-
ity of heparin to release intracellular TFPIα. This is in
contrast to the findings of Ellery and co-workers in
HUVECs [32], but consistent with those observed by
Zhang et al. [6] and Mast and colleagues [33] in
HUVEC, ECV406, and EA.hy926 cells and in human
Figure 3 Heparin treatment of Sum102 and MDA-MB-231 cells. Serum-starved cells were treated with SFM (untreated) or heparin (5 U/mL)
for 2 hours or with PI-PLC + heparin (2+2 hours) before the supernatant was removed and cells lysed or collected for flow cytometry analysis.
The supernatant was discarded after PI-PLC pre-treatment. Free and total TFPI antigen measured in the supernatant (A and C) and lysate
(B and D) of untreated, heparin or PI-PLC + heparin treated Sum102 (A and B) and MDA-MB-231 (C and D) cells. Mean values + SD (n ≥ 9) of
three to six independent experiments are presented. Statistical comparisons were conducted between heparin/PI-PLC+heparin treated samples
and untreated controls. (E) Flow cytometry analysis of untreated (black, solid) and heparin treated (black, dotted) Sum102 (left panel) and MDA-
MB-231 (right panel) cells. One representative experiment of three is shown.
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placenta. Contradictory to a previous report on endothe-
lial cells [6] we did not observe any additional release of
cell surface attached TFPI by heparin after PI-PLC pre-
treatment in our cells. Our methodology is virtually the
same, and it is therefore likely that this discrepancy may
be due to yet unrevealed cell type specific characteristics
like differences in the expression of other TFPI binding
cell surface molecules such as syndecans [34].
When looking further into the characteristics of the
different breast cancer cell lines, we discovered a similar
substantial variation in the TF mRNA expression as
observed for TFPI. The MDA-MB-231 and MCF-7 cells
have previously been shown to express high and low
levels of TF [35], respectively, which support our find-
ings. Interestingly, the TF mRNA and antigen levels cor-
related well with the subtype and degree of invasiveness
of the cells, supporting the tumor growth promoting na-
ture of TF [13-18,36,37]. In accordance with the expres-
sion levels, the TF activity was greater in MDA-MB-231
cells than in Sum102 cells reflecting that TF was in fact
more abundant on the surface of these cells. Moreover,
the low TF expression in the HCAEC cells was reflected
by the low levels of FXa generated in the assay and the
inability to further reduce FXa activity after TF blocking.
The increase in TF activity following PI-PLC treatment
of Sum102 and HCAEC cells also indicated that the
GPI-attached, cell surface TFPI was able to inhibit TF-
FVIIa and/or FXa activity on the same cell. The immu-
nostaining results also confirmed association of TFPI
and TF at the cell surface. Thus, GPI-attached TFPI
expressed by breast cancer cells was able to directly
interfere with the TF activity on the cell surface and may
therefore have implications for the pro-cancer nature of
TF. Although we were unable to differentiate between
TFPIα and TFPIβ in the procoagulant assay, TFPIβ
appeared to be the most abundant isoform on the cell
surface and we have previously observed that overex-
pression of TFPIα and TFPIβ separately suppressed
breast cancer cell growth by inhibiting cell proliferation
and increasing apoptotic activity [20], indicating func-
tional importance of both isoforms. However, it remains
to clarify whether the GPI-attached TFPI is indeed able
to inhibit TF signaling, which is important in the pro-
tumor effect of TF [18], or if the effects are due to sig-
naling mechanisms independent of TF. Overexpression
of TFPI in breast cancer cells conducted in previous
experiments resulted in an increase in TF, PAR-1, and
PAR-2 mRNA levels, which may indicate that TFPI is in
fact able to affect TF signaling [20]. Pre-treatment with
anti-TFPI blocking antibody increased TF activity even
more than PI-PLC treatment, indicating the presence of
non-GPI-attached cell surface TFPI that might possess
anticoagulant activity.
Conclusions
We provide evidence for the expression of both isoforms
of TFPI (TFPIα and TFPIβ) in tumor derived breast can-
cer cell lines. The TFPI expression associated to some
extent with the TF expression and the invasiveness and
basal- or luminal-like subtype of the cells. TFPIα was
secreted by the cells or remained cell-associated either
bound to the surface indirectly through a GPI anchor or
located in intracellular, heparin-releasable pools. TFPIβ
was exclusively found on the cell surface attached
through a GPI anchor. PI-PLC-releasable, GPI-attached
cell surface TFPI co-localized with TF and inhibited TF-
FVIIa activity and the removal of such anchored proteins
allowed for the additional release of intracellular TFPIα
by heparin. Furthermore, flow cytometry, immunofluor-
escence, and FXa activity measurements suggested the
presence of a non-GPI bound cell surface associated
TFPI pool with anticoagulant properties. Similar com-
plex features of the two isoforms of TFPI were observed
in breast cancer cells and in endothelial cells, although
the variation in TFPI levels in the different breast cancer
cell lines demonstrated a tumor-associated regulative
control of the endogenous TFPI expression. Our findings
indicate a possible functional implication of TFPIβ in lo-
cally reducing TF signaling and breast cancer cell pro-
gression, further endorsing involvement of TFPI in
malignant disease.
Materials and methods
Reagents
RPMI1640, Dulbecco’s modified Eagle’s medium (DMEM),
Endothelial Basal Medium-2 (EBM-2), EGM-2-MV Sin-
gleQuots, fetal bovine serum (FBS) and phosphate buf-
fered saline (PBS) were purchased from Lonza (Viviere,
Belgium), while the Human mammary epithelial cell
(HuMEC) ready medium, Alexa FluorW 488 goat anti-
(See figure on previous page.)
Figure 4 PI-PLC and heparin treatment of HCAEC cells. Serum-starved cells were treated with SFM (untreated), PI-PLC (1 U/mL), or heparin
(5U/mL) for 2 hours or with PI-PLC + heparin (2+2 hours) before the supernatant was removed and cells lysed or collected for flow cytometry
analysis. The supernatant was discarded after PI-PLC pre-treatment. Total and free TFPI antigen measured in the supernatant (A and C) and cell
lysate (B and D) of untreated/PI-PLC (A and B) and untreated/heparin/PI-PLC+heparin (C and D) treated HCAEC cells. Mean values (n ≥ 5;
supernatant, n = 4; cell lysate) + SD of two independent experiments. Statistical comparisons were conducted between PI-PLC or heparin/PI-PLC
+heparin treated samples and untreated controls. (E) Flow cytometry analysis of untreated (black, solid), PI-PLC (black, broken, left panel), and
heparin (black, dotted, right panel) treated HCAEC cells. One representative experiment of three is shown.
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rabbit IgG (H+L) antibody (A-11008), and SlowFadeW
Gold antifade reagent w/DAPI (S36938) were from Life
Technologies (Carlsbad, CA, USA). The polyclonal rabbit
anti-human tissue factor pathway inhibitor antibody (4901/
ADG72), monoclonal mouse anti-human tissue factor path-
way inhibitor antibody (4903), and monoclonal mouse anti-
human tissue factor antibody (ADG4508) were from
American Diagnostica (Greenwich, CT, USA), while the
rabbit-IgG-UNLB and goat anti-rabbit IgG (H+L)-RPE
antibodies were from Southern Biotechnology Associates
(Birmingham, AL, USA). The human γ-globulin antibody,
PI-PLC, and formalin solution (4% formaldehyde, HT5011)
were from Sigma-Aldrich (St. Louis, MO, USA). Heparin
was purchased from Leo Pharma (Ballerud, Denmark). The
RNaqueous kit (AM1912), High Capacity cDNA Reverse
Transcription Kit, TaqMan Gene Expression Master Mix,
TaqMan TF assay (Hs00175225_m1), and pre-developed
TaqMan Human 18S rRNA assay were all from Applied
Biosystems (Life Technologies). Purified bovine FX, FXa,
and FXa chromogenic substrate CS-11(22) were from
Figure 5 Cell surface anticoagulant activity of PI-PLC treated cells. Confluent Sum102, MDA-MB-231, and HCAEC cells grown in 24-wells
trays were treated with SFM (untreated), PI-PLC, monoclonal anti-TFPI antibody, or anti-TF antibody for 2 hours before the supernatant was
removed and cells were washed and assayed for TF activity. Sum102 (A), MDA-MB-231 (B), and HCAEC (C) cells were incubated with FVIIa and FX
for 1 hour before the reaction was stopped and a substrate to FXa was added. The results were analyzed colorimetrically at 405 nm. The amount
of FXa generated is displayed as mean mU/mL + SD (n ≥ 7) of three to four independent experiments. Statistical comparisons were conducted
between PI-PLC treated samples and untreated controls. (D) Fluorescence images of SFM + Glycerol (untreated, upper panels) and PI-PLC
(bottom panels) treated Sum102 cells stained with antibodies against both isoforms of TFPI (green, left panels) and TF (red, middle-left panels).
After merging the images, co-localization of the two antibodies was indicated by a yellow color (middle-right panels). Nuclear staining with DAPI
is depicted in the left panels. One representative experiment of three is shown.
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Aniara Diagnostica (Mason, OH, USA), while recombinant
FVIIa was from Novo Nordisk AS (Bagsvaerd, Denmark).
Cell cultures
The human mammary adenocarcinoma cell lines SK-BR-
3 (ATCC HTB-30) and MCF-7 (ATCC HTB-22) and the
human mammary ductal carcinoma cell lines ZR-75-1
(ATCC CRL-1500) and BT-474 (ATCC HTB-20) were
grown in RPMI1640 with phenol red and 2 mM L-
glutamine supplemented with 10% heat inactivated FBS.
The intraductal carcinoma cell lines Sum102 and
Sum149 and the transformed breast epithelial cell line
ME16C2 (hTERT-HME1, ATCC CRL-4010) were grown
in HuMEC ready medium containing HuMEC supple-
ments (epidermal growth factor, hydrocortisone, isopro-
tenerol, transferrin and insulin) and Bovine Pituitary
Extract. 5% heat-inactivated FBS was included in the
growth medium of Sum149 cells. The human mammary
adenocarcinoma cell line MDA-MB-231 (ATCC HTB-
26), the human endothelial cell line EA.hy926 (ATCC
CRL-2922), and the Chinese hamster ovary cell line
CHO-K1 (ATCC CCL-61) were cultured in DMEM con-
taining 2 mM L-glutamine, 4.5 g/L glucose and 10% heat
inactivated FBS. The primary human coronary artery
endothelial cells HCAEC (#CC-2585, Lonza) were culti-
vated in modified EBM-2 basal medium supplemented
with EGM-2-MV SingleQuots (containing vascular
endothelial growth factor, basic fibroblast growth factor,
insulin-like growth factor-I, epidermal growth factor, as-
corbic acid, and gentamicin), and 10% FBS. All cells
were cultured at 37°C in an incubator with a humidified
atmosphere and 5% CO2.
Quantitative real-time PCR
Total RNA was isolated from the cells using the RNaqu-
eous kit according to the manufacturer’s protocol, and
the concentration of the isolated RNA was assessed by
the NanoDrop1 ND-1000 UV–vis Spectrophotometer
(NanoDrop Technologies, Wilmington, DE, USA). cDNA
was synthesized from total RNA using the High Capacity
cDNA Reverse Transcription Kit, and 19 ng of cDNA
were PCR amplified on the ABI PRISM 7900 Sequence
Detection System (Applied Biosystems) according to the
protocol, using the TaqMan Gene Expression Master
Mix, and the self-designed TFPIα and TFPIβ specific
assays [21] or a Taqman TF assay. All samples were run
in triplicate. The relative mRNA expression was calcu-
lated using the comparative Ct method, normalizing the
Ct values against the endogenous control 18S rRNA, and
using HCAEC expression as a normal endothelial refer-
ence and CHO expression values as a negative sample.
The 18S rRNA showed the least expression variation be-
tween the different cell lines of the endogenous controls
tested.
TFPI and TF antigen
To determine TFPI and TF protein expression, cells
were seeded in six-well trays and grown for three days
until ~80% confluence before harvesting. Media were
collected and cells were lysed as previously described
[20]. The commercial ELISA kits Free and Total TFPI
(AsserachromW, Diagnostica Stago, Asnière, France)
were used to measure TFPI antigen in the cell media/lys-
ate, and Zymutest Tissue Factor full length (RK035A,
Hyphen BioMed) to measure full length TF in cell
lysates, according to the manufacturers’ protocols. The
results were corrected against cellular total protein, as
measured in cell lysates by the modified Lowry assay
(Bio-Rad DC Protein Assay, Bio-Rad Laboratories,
Hercules, CA, USA).
PI-PLC and heparin treatment
Confluent cells in six-wells trays were washed three
times with PBS and serum starved for one hour before
treated with PI-PLC (1 U/mL), or heparin (5 U/mL) for
two hours, or with PI-PLC for two hours followed by re-
moval of the supernatant and subsequent treatment with
heparin for additional two hours, at 37°C. Serum-free
media (SFM) was used as a control for the treatments. A
second control containing SFM and glycerol from a 55%
solution with 0.05% NaN3 to mimic the PI-PLC buffer
was also tested but showed no differences from SFM
alone. The supernatants were collected and analyzed for
TFPI antigen, while the cells were washed twice with
PBS and collected for flow cytometry analysis or lysed as
previously described [20] for antigen detection.
Flow cytometry
Immediately after treatment, Sum 102, MDA-MB-231,
and HCAEC cells were detached using 5 mM EDTA and
transferred to Eppendorf tubes. Cells were washed twice
in cold PBS before blocked with human γ-globulin (100
μg/mL) in dilution buffer (PBS with 1% BSA and 12.5
mM Na-Azide) for 15–20 min. Cells were incubated
with a rabbit anti-human TFPI specific antibody or an
irrelevant rabbit antibody at a final concentration of 40
ng/μl for 30 min at 4°C. Cells were washed twice in cold
PBS and stained with RPE linked goat anti-rabbit anti-
body for 30 min at 4°C, before pelleted cells were resus-
pended in dilution buffer. Flow cytometry analysis was
performed on the FACSCalibur flow cytometer (Becton
Dickinson, Heidelberg, Germany), and the CellQuest 3.3
software (BD Biosciences) was used for data collection.
Flow data were analyzed and presented using Flow Jo
7.6.4 (Tree Star, Inc., Ashland, OR).
Immunofluorescence microscopy
Sum102 cells (1.0⋅105/well) were seeded the day before
in 4-wells glass chamber slides (Lab Tek II, Thermo
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Fisher Scientific, Waltham, MA), serum-starved for 1
hour and treated with SFM containing glycerol from a
55% solution with 0.05% NaN3 (denoted untreated) or
PI-PLC (1 U/mL) for 2 hours at 37°C. After treatment,
the cells were washed once in PBS, fixed with formalin
for 20 min on ice, washed once with PBS (with 1% FBS)
and incubated 20 min at RT with blocking buffer (PBS
with 5% BSA and 1% Tween 20). After blocking, the
cells were washed once in dye buffer (PBS with 1% BSA
and 1% Tween 20) and incubated with primary rabbit
anti-human TFPI and mouse anti-human TF specific
antibodies for 45 min at RT. Cells were washed three
times with dye buffer and stained with fluorescent goat
anti-rabbit and donkey anti-mouse secondary antibodies
for 45 min at RT. The cells were washed three times
with dye buffer, the chambers were released from the
slides, and two drops of antifade solution were added
and the slides sealed with cover glass. Stained cells were
visualized using a fluorescence Nikon eclipse E400
inverted microscope with a Plan Fluor 40x/0.75 DIC M
objective (Nikon, Tokyo, Japan) and the appropriate fil-
ter. Images were captured using a Nikon digital sight
DS-Fi1 Camera system.
TF-FVIIa activity
Sum102 (1.5⋅105/well), MDA-MB-231 (0.5⋅105/well),
and HCAEC (0.7⋅105/well) cells were seeded the day
prior to the experiment, serum-starved for 1 hour and
treated with SFM (denoted untreated), PI-PLC (1 U/
mL), TFPI blocking antibody (10 μg/mL), or TF blocking
antibody (10/20 μg/mL) for 2 hours at 37°C. After treat-
ment, the cells were washed twice in wash solution (10
mM HEPES, 150 mM NaCl, 4 mM KCl, and 11 mM
Glucose, pH 7.5) and incubated for 1 hour at 37°C in re-
action solution (wash buffer with 5 mg/mL BSA and 5
mM CaCl2, pH 7.5) containing 10 nM FVIIa and 175
nM FX. Following incubation, 50 μL were transferred to
100 μL stop solution (50 mM Tris HCl, 150 mM NaCl,
25 mM EDTA, and 1 mg/mL BSA, pH 7.5) on ice before
incubated with 50 μL CS-11(22) substrate. The absor-
bance at 405 nm was recorded at 37°C for 45 min at 15
sec intervals using a Spectra Max Plus 384 microplate
reader (Molecular Devices, Sunnyvale, CA, USA). The
maximum velocities (Vmax) in mU/min were used to cal-
culate the amount of FXa generated, using a standard
curve obtained with known concentrations of FXa.
Western blotting
Supernatants from Sum102 cells treated with SFM con-
taining glycerol from a 55% solution with 0.05% NaN3
(denoted untreated) or PI-PLC were collected and degly-
cosylated using the Enzymatic Protein Deglycosylation Kit
(Sigma-Aldrich) following the manufacturer’s instruction,
combined with loading buffer (Bio-Rad Laboratories
Hercules, CA) containing 5% β-mercaptoethanol and
denatured for 5 min at 97°C. The concentrated superna-
tants were separated on a 10% SDS-polyacrylamide gel
(Bio-Rad), before proteins were transferred to a PVDF
membrane (Bio-Rad), blocked in 5% BSA, and incubated
with a primary anti-human TFPI specific antibody over
night at 4°C under constant agitation. After incubation
with the appropriate secondary HRP-linked antibody for 1
hour at 20°C, proteins were visualized using the ECL
Plus Western Blotting Detection System (GE Healthcare,
Buckinghamshire, UK). Images were produced using the
Luminescent Image Analyzer LAS-4000 mini (Fujifilm,
Tokyo, Japan).
Statistical analysis
The associations between mRNA and protein levels
were evaluated using Pearsons correlation test, while sig-
nificant differences between treated samples and con-
trols were calculated using the Student’s t or one-way
ANOVA (Bonferroni corrected) tests in GraphPad Prism
5.0 (Graphpad, San Diego, CA, USA), and a P-value of
<.05 was considered statistically significant. * = p<.05,
** = p<.01, and *** = p<.001.
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